Scientists are developing all sorts of potential new treatments to tackle the most difficult cancer cases—including some that ...

New imaging tools reveal how within an hour of infection, the virus begins to alter our chromosomes to kick-start its own replication.

A new treatment for advanced melanoma is showing promising results for people whose tumors have stopped responding to ...

Herpes simplex virus type 1 (HSV-1) is normally associated with cold sores – they can be annoying and unsightly, but for otherwise healthy adults they’re not normally a serious threat. However, it ...

The combination of RPI, a genetically engineered herpes simplex virus type 1, and Opdivo shrank both injected and non-injected tumors by 30%.

The cold sore-causing Herpes Simplex Virus (HSV-1) hijacks human cells and reconfigures its DNA within just an hour after infection, according to a new study that may help tackle the pathogen. Viruses ...

University of Southern California researchers have found a way to rebrand this oft-embarrassing sore subject by genetically modifying HSV-1 and administering it to patients with treatment-resistant, ...

The herpes simplex virus type 1 (HSV-1), which affects almost two-thirds of the world's population and is generally ...

Aug. 18, 2020 — Infectious disease researchers have used a gene editing approach to remove latent herpes simplex virus 1, or HSV-1, also known as oral herpes. In animal models, the findings show ...

Herpes simplex virus type 1 is best known as the culprit behind cold sores. When it’s not causing itchy, crusty sores on the mouth, it hides in the bundle of nerves that run through the face.

Two previous studies of a herpes simplex virus type 2 (HSV-2) subunit vaccine containing glycoprotein D in HSV-discordant couples revealed 73% and 74% efficacy against genital disease in women who ...

The global market for Herpes Simplex Virus Infections was valued at US$5.2 Billion in 2024 and is projected to reach US$6.6 Billion by 2030, growing at a CAGR of 3.9% from 2024 to 2030.